Betr.: Nahrungsergaenzunsmittel ALEN
Irrefuehrung des Verbrauchers, falsche Gesundheits-und Heilaussagen lt.
> Federal Trade Comision ( FTC) USA Novel-Food;
> Nahrungsergaenzungsmittel "ALEN".
>
> Wie der folgende ofizielle Bericht der FTC USA zeigt sind alle im Bericht genannten gesundheitsbezogenen Heilaussagen des Herstellers
> von "ALEN" gegen Geld-Strafe (11.000,-US pro Verstoss) in den USA strengstens
> verboten.
>
> Sie koennen direkt ueber www.ftc.gov alle rechtskraefigen
> US-Urteile der FTC gegen unhaltbare ALEN - Heilaussagen finden.
>
> Venegas Inc
> venegas.htm, Search in: News Releases
> File size: 7K, Create Date: Aug-28-98 00:00
> http://www.ftc.gov/opa/1997/9710/venegas.htm
>
> 2: Venegas Inc
> ftc2.htm, Search in: News Releases
> File size: 9K, Create Date: Aug-28-98 00:00
> http://www.ftc.gov/opa/1997/9710/ftc2.htm
>
> 3: LA FTC, LAS AUTORIDADES MEXICANAS, Y LOS FUNCIONARIOS ESTATALES
> CONTINUAN LA CAMPAÑA PARA DETENER LA PUBLICIDAD FRAUDULENTA DIRIGIDA A LOS
> CONSUMIDORES DE HABLA HISPANA
> alerta2.htm, Search in: News Releases
> File size: 15K, Create Date: Jun-29-98 00:00
> http://www.ftc.gov/opa/1998/9806/alerta2.htm
>
> 4: FTC, Mexican Authorities and State Officials Continue Campaign to Halt
> Fraudulent Advertising
> alerta-2.htm, Search in: News Releases
> File size: 13K, Create Date: Aug-28-98 00:00
> http://www.ftc.gov/opa/1998/9806/alerta-2.htm
>
> 5: Announced Actions for January 27, 1998
> petapp5-98.htm, Search in: News Releases
> File size: 3K, Create Date: Aug-28-98 00:00
> http://www.ftc.gov/opa/1998/9801/petapp5-98.htm
>
MARKETER OF DIETARY SUPPLEMENT ADVERTISED THROUGH SPANISH-LANGUAGE MEDIA
> AGREES TO SETTLE FTC CHARGES OF UNSUBSTANTIATED BENEFITS CLAIMS FOR PRODUCT
>
> > A Brooklyn, New York-based seller of a dietary
> supplement has agreed to settle Federal Trade
> Commission charges that it made unsubstantiated
> health benefits claims for "Alen," a powdered
> nutritional supplement comprised of wheat germ,
> wheat bran, soybean extract, and seaweed extract.
> Advertisements for "Alen" -- appearing primarily
> in Spanish language media in New York City in
> such publications as El Diario, a Spanish
> language newspaper and on a local Spanish
> language television station -- contained claims,
> among others, that "Alen" delays the aging
> process, eliminates anemia, controls addiction to
> excess fat and sweets, and helps diabetics
> naturally produce insulin. The FTC charged that
> the seller, Venegas Inc., and company owner and
> officer, Angel Venegas, did not possess competent
> and reliable substantiation for such claims. A
> proposed settlement of these charges would
> prohibit the company and its owner from making
> any representations about the health benefits,
> performance, or efficacy of any food, drug, or
> dietary supplement without possessing competent
> and reliable scientific evidence to support the
> claims.
> >
> > This past June, officials from the Mexican
> government, the FTC, the Food and Drug
> Administration, and seven state Attorneys General
> announced "Campaña Alerta," an innovative and
> unprecedented effort to prevent deceptive
> advertisements directed at Spanish-speaking
> consumers. The joint law enforcement and public
> education campaign targets Spanish-language ads
> that deceptively market health care products and
> treatments, and informs consumers about how best
> to protect themselves against health fraud.
> >
> > According to the FTC's complaint detailing the
> allegations in this case, print advertisements
> for "Alen" contained representations that "Alen:"
> >
> > a.. increases life expectancy;
> > b.. delays the aging process;
> > c.. eliminates anemia;
> > d.. increases the immune system's defenses;
> > e.. increases memory and scholastic performance;
> > f.. helps diabetics naturally produce insulin;
> > g.. reduces the pain of rheumatism and
> migraines;
> > h.. lowers blood pressure;
> > i.. helps heal ulcers;
> > j.. increases muscle bulk;
> > k.. controls addictions to excess fat and
> sweets; and
> > l.. protects against infections and increases
> and enhances the healing process.
> > The FTC's complaint alleges that Venegas
> falsely represented that it possessed and relied
> upon a reasonable basis that substantiated these
> representations.
> >
> > The proposed settlement to these charges,
> announced today for a public comment period
> before the Commission determines whether to make
> the settlement final and binding, would prohibit
> respondents Venegas Inc., and Angel Venegas, from
> making each of the specific representations
> alleged in the complaint for "Alen," or from
> making any representations as to the benefits,
> performance, or efficacy of any food, drug or
> dietary supplement, without possessing and
> relying upon competent and reliable scientific
> evidence to support the claims. The proposed
> settlement would permit the respondents to make
> representations specifically permitted in the
> labeling for any product by regulations
> promulgated by the Food and Drug Administration's
> (FDA) Nutrition Labeling and Education Act of
> 1990, and would permit the respondents to make
> any representation for any drug that is permitted
> by the FDA in the drug's labeling.
> >
> > A summary of the proposed consent agreement
> will be published in the Federal Register
> shortly, and will be subject to a 60-day public
> comment period. Comments should be addressed to
> the FTC, Office of the Secretary, 6th Street and
> Pennsylvania Avenue, N.W., Washington, D.C.
> 20580. This news release will also be issued in
> Spanish, and the FTC welcomes comments submitted
> in Spanish.
> >
> > This matter was investigated by the FTC's New
> York Regional Office. The Commission vote to
> accept the proposed agreement for public comment
> was 4-0.
> >
> > NOTE: A consent agreement is for settlement
> purposes only and does not constitute an
> admission of a law violation. When the Commission
> issues a consent order on a final basis, it
> carries the force of law with respect to future
> actions. Each violation of such an order may
> result in a civil penalty of $11,000.
>
> > Copies of the consent agreement and an analysis
> of the agreement to assist the public in
> commenting are available on the Internet at the
> FTC's World Wide Web Site at: http://www.ftc.gov
> or by calling 202-326-3627. Copies of documents
> stemming from "Campaña Alerta" and other FTC
> documents are also available from the FTC's
> Public Reference Branch, Room 130, 6th Street and
> Pennsylvania Avenue, N.W., Washington D.C. 20580;
> 202-326-2222; TTY for the hearing impaired
> 202-326-2502. To find out the latest news as it
> is announced, call the FTC's NewsPhone recording
> at 202-326-2710.
> >
> > MEDIA CONTACT:
> > Howard Shapiro
> > Office of Public Affairs
> > 202-326-2176
> >
> > STAFF CONTACT:
> > Michael J. Bloom, Donald G. D'Amato or Denise
> Tighe
> > New York Regional Office
> > 150 William Street, Suite 1300
> > New York, New York 10038
> > 212-264-1207
> >
> > (FTC File No. 962 3218)
> >
> > (Venegas)
|
